The clinical problem
Long-term NSAID use increases the risk of gastroduodenal ulcers, creating a need for effective, tolerable gastroprotection during sustained anti-inflammatory therapy.
Study at a glance
Tegoprazan was non-inferior to lansoprazole for preventing gastroduodenal ulcers at 24 weeks
The study supports non-inferiority for ulcer prevention, not superiority. Per-group ulcer incidence magnitudes were not provided in the brief, so the endpoint is shown as a verdict panel rather than a comparative bar chart.
Efficacy & symptom outcomes
| Endpoint | Finding | Reported statistic | Interpretation |
|---|---|---|---|
| Peptic ulcer incidence at week 24 | Tegoprazan 25 mg was non-inferior to lansoprazole 15 mg | p=0.0004 | Primary endpoint met; supports comparable ulcer prevention. |
| Heartburn-free rate at week 12 | Higher with tegoprazan than lansoprazole | p=0.0421 | Symptom signal favoring tegoprazan at week 12. |
| Other NSAID-induced GI symptom-free rates | No significant difference reported | Not significant | Broadly comparable symptom control across other assessed symptoms. |
Chart omitted intentionally: the brief reports statistical conclusions and p-values but not per-group outcome magnitudes for ulcer incidence or symptom-free rates.
Safety profile
Reported as comparable between tegoprazan and lansoprazole in the study summary.
No meaningful imbalance was highlighted in the provided brief; overall tolerability was comparable.
Tegoprazan may be presented as a clinically effective alternative to lansoprazole for gastroprotection in patients needing long-term NSAIDs, with comparable safety and tolerability; frame the evidence as non-inferiority, not superiority for ulcer prevention.